Literature DB >> 26767054

Log odds of positive lymph nodes are superior to other measures for evaluating the prognosis of non-small cell lung cancer.

Peng Lv1, Gang Chen2, Peng Zhang1.   

Abstract

BACKGROUND: To evaluate the ability of the log odds of positive lymph nodes to predict prognosis in patients with non-small cell lung cancer (NSCLC).
METHODS: Correlations between the log odds of positive lymph nodes, numbers of dissected lymph nodes, dissected lymph node stations, positive lymph nodes, positive lymph node ratio, and positive lymph node stations were retrospectively evaluated using Pearson correlation coefficients (r), survival analysis by Kaplan-Meier, Cox hazard ratio model, and log-rank tests.
RESULTS: The numbers of dissected lymph nodes, positive lymph nodes, dissected lymph node stations and positive lymph node stations significantly correlated with the log odds of positive lymph nodes (P < 0.001, P < 0.001, P = 0.002 and P < 0.001, respectively). The five-year survival ratio of postoperative patients with the log odds of positive lymph nodes <11.412 and >-1.412 were 63.9% and 32.5%, respectively (P < 0.001). According to multivariate analysis, age and log odds of positive lymph nodes are independent risk factors for overall survival (hazard ratio = 2.660, 95% confidence interval 2.114-3.346, P < 0.001). A new staging system featuring a combination of log odds of positive lymph nodes and a tumor node metastasis (TNM) staging system was established for predicting survival.
CONCLUSION: The log odds of positive lymph nodes are superior to the positive lymph node ratio and p-N-stage for predicting prognosis of NSCLC. A new staging system that combines log odds of positive lymph nodes and the current TNM staging system predicts prognosis more accurately than the TNM system alone.

Entities:  

Keywords:  Log odds; non-small cell lung cancer; staging system

Year:  2014        PMID: 26767054      PMCID: PMC4704327          DOI: 10.1111/1759-7714.12145

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  18 in total

1.  Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.

Authors:  Chang-Li Wang; Yue Li; Dong-Sheng Yue; Lian-Min Zhang; Zhen-Fa Zhang; Bing-Sheng Sun
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

2.  Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer.

Authors:  Robert A Ramirez; Christopher G Wang; Laura E Miller; Courtney A Adair; Allen Berry; Xinhua Yu; Thomas F O'Brien; Raymond U Osarogiagbon
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

3.  Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection.

Authors:  Zhe Sun; Yan Xu; De Ming Li; Zhen Ning Wang; Guo Lian Zhu; Bao Jun Huang; Kai Li; Hui Mian Xu
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

Review 4.  Prognostic value of nodal ratios in node-positive breast cancer.

Authors:  Wendy A Woodward; Vincent Vinh-Hung; Naoto T Ueno; Yee Chung Cheng; Melanie Royce; Patricia Tai; Georges Vlastos; Anne Marie Wallace; Gabriel N Hortobagyi; Yago Nieto
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Which is the better prognostic factor for resected non-small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification?

Authors:  Shenhai Wei; Hisao Asamura; Riken Kawachi; Hiroyuki Sakurai; Shun-ichi Watanabe
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

6.  Reasonable extent of lymph node dissection in intentional segmentectomy for small-sized peripheral non-small-cell lung cancer: from the clinicopathological findings of patients who underwent lobectomy with systematic lymph node dissection.

Authors:  Yuki Matsumura; Tomoyuki Hishida; Junji Yoshida; Keiju Aokage; Genichiro Ishii; Kanji Nagai
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

Review 8.  Lung cancer surgery: an up to date.

Authors:  Nikolaos Baltayiannis; Michail Chandrinos; Dimitrios Anagnostopoulos; Paul Zarogoulidis; Kosmas Tsakiridis; Andreas Mpakas; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

9.  Risk factors for both recurrence and survival in patients with pathological stage I non-small-cell lung cancer.

Authors:  Yoshiki Kozu; Tomohiro Maniwa; Shoji Takahashi; Mitsuhiro Isaka; Yasuhisa Ohde; Takashi Nakajima
Journal:  Eur J Cardiothorac Surg       Date:  2013-04-04       Impact factor: 4.191

10.  The tumor-log odds of positive lymph nodes-metastasis staging system, a promising new staging system for gastric cancer after D2 resection in China.

Authors:  Miao-zhen Qiu; Hui-juan Qiu; Zhi-qiang Wang; Chao Ren; De-shen Wang; Dong-sheng Zhang; Hui-yan Luo; Yu-hong Li; Rui-hua Xu
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

View more
  2 in total

1.  Construction and validation of nomograms based on the log odds of positive lymph nodes to predict the prognosis of lung neuroendocrine tumors.

Authors:  Suyu Wang; Juan Wei; Yibin Guo; Qiumeng Xu; Xin Lv; Yue Yu; Meiyun Liu
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

2.  Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study.

Authors:  Yue Yu; Peng Zhang; Renqi Yao; Junnan Wang; Pei Wang; Xiaofei Xue; Jian Xiao; Zhinong Wang
Journal:  Transl Lung Cancer Res       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.